This is an exciting time for anyone suffering from early onset Alzheimer's disease.   A new drug that should get FDA approval by the end of this year, would expand the treatment options for the more than 6 million Americans of all ages who have Alzheimer's. The disease is the fifth-leading cause of death for adults over 65. Donanemab, a drug developed by Eli Lilly and Company, showed promising results in clinical trials. The drug eliminates brain plaques associated with Alzheimer's. Studies show the drug could be a breakthrough in treating early stages of the disease, slowing cognitive decline in those with early symptoms.

Joe Montminy is a patient advocate who is living with younger onset dementia and is currently serving on the MA/NH Alzheimer’s Association Board of Directors and the New England Alzheimer’s Association Early-Stage Advisory group. He used to live in CT and was diagnosed at 54 years old, it took 3 years before he could get a correct diagnosis. Joe says he is optimistic that this new drug and exciting new blood testing to get an earlier diagnosis, is going to make a big difference. Joe keeps a very positive attitude and finds comfort in a support group.  Kristen Cusato is the Director of Communications for the Alzheimer's Association Connecticut Chapter & she is a New England Research champion. Kristen thinks that education is key and knowing the early signs of the disease, which can lead to an early diagnosis and treatment. She believes people like Joe can help with his advocacy, but more importantly he can bring hope with his story of struggle with early onset Alzheimer's disease.

To get in touch with the CT chapter of the Alzheimer's Association: Connecticut Chapter (alz.org)

To get information or to apply for benefits: CT Paid Leave

https://ctpaidleave.org/s/?language=en_US



https://www.facebook.com/CTPaidLeave



https://www.instagram.com/ctpaidleave/



https://twitter.com/CTPaidLeave



https://www.youtube.com/results?search_query=ct+paid+leave